PCD CPH 2016

Dr Payne (University College Hospital, London, UK) chairs a discussion for ecancertv with Prof Danesi (University of Pisa, Pisa, Italy), Prof da Costa (Hospital de Santa Maria, Lisbon, Portugal) and Prof Mulders (Radboud University, Nijmegen, The Netherlands) about the main points coming from the 2016 Prostate Debate in Copenhagen. In particular, they discuss the role of docetaxel chemotherapy in hormone-sensitive prostate cancer and the role of drug combinations such as zoledronic acid and celecoxib. They discuss the impact of the STAMPEDE trial, along with discussion of androgen deprivation therapy, COX inhibitors and side effects. They also consider less invasive diagnosis and monitoring methods which harness blood-based biomarkers.